Farxiga Archives -

AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its

AstraZeneca raises 2022 guidance, names Demaré as non-exec chair

https://pharmaphorum.com/news/astrazeneca-raises-2022-guidance-names-demare-as-non-exec-chair/

News/ News/ R&D

AZ bites back at rivals with new Farxiga data in heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiovascular disease, Eli Lilly, Farxiga, heart failure 0 Comment

AstraZeneca’s SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it

AZ bites back at rivals with new Farxiga data in heart failure

https://pharmaphorum.com/news/az-bites-back-at-rivals-with-new-farxiga-data-in-heart-failure/

News/ News/ R&D

Stage set for Jardiance to become universal heart failure drug

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Farxiga, heart failure, Jardiance 0 Comment

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting

Stage set for Jardiance to become universal heart failure drug

https://pharmaphorum.com/news/stage-set-for-jardiance-to-become-universal-heart-failure-drug/

Market Access/ News/ News

Jardiance gets parity with Farxiga in US as FDA clears use in heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiology, Eli Lilly, Farxiga, fda, heart failure, Jardiance, regulatory approval 0 Comment

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with

Jardiance gets parity with Farxiga in US as FDA clears use in heart failure

https://pharmaphorum.com/news/jardiance-gets-parity-with-farxiga-in-us-as-fda-clears-use-in-heart-failure/

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

News/ News/ Sales and Marketing

AZ gets European approvals for Forxiga in chronic kidney disease

Phil Taylor AstraZeneca, Boehringer Ingelheim, chronic kidney disease, Eli Lilly, EU, Farxiga, Forxiga, Jardiance, UK 0 Comment

AstraZeneca’s Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with

AZ gets European approvals for Forxiga in chronic kidney disease

https://pharmaphorum.com/news/az-gets-european-approvals-for-forxiga-in-chronic-kidney-disease/

News/ News/ Sales and Marketing

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss

Phil Taylor AstraZeneca, coronavirus, COVID-19, COVID-19 vaccine, Farxiga, Financial, Imfinzi, Lynparza, Tagrisso 0 Comment

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss

https://pharmaphorum.com/news/azs-covid-19-jab-sales-top-1-2bn-but-come-at-a-loss/

News/ News/ R&D

Boehringer, Lilly hail Jardiance data in hard-to-treat heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, Farxiga, heart failure, Jardiance, Novartis 0 Comment

Boehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance

Boehringer, Lilly hail Jardiance data in hard-to-treat heart failure

https://pharmaphorum.com/news/boehringer-lilly-hail-jardiance-data-in-hard-to-treat-heart-failure/

News/ News/ Sales and Marketing

AZ closes in Forxiga kidney disease label in EU after nod from CHMP

Phil Taylor AstraZeneca, Boehringer Ingelheim, CHMP, chronic kidney disease, Eli Lilly, Farxiga, Forxiga, Jardiance 0 Comment

AstraZeneca’s fast-growing SGLT2 inhibitor Forxiga could soon get a further boost from approval in the EU as a

AZ closes in Forxiga kidney disease label in EU after nod from CHMP

https://pharmaphorum.com/news/az-closes-in-forxiga-kidney-disease-label-in-eu-after-nod-from-chmp/

News/ News/ Sales and Marketing

Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiology, Eli Lilly, Farxiga, heart failure, Jardiance 0 Comment

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will

Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance

https://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/

Trending

Farxiga

Login